ACR16

Published In 1999 journal of Neurology; There was an HD person who forthe previous 2 years could no longer feed herself or drink withoutspilling. She had moderate chorea (about 40 chorea movements everyminute) and suffered falls about twice a week. She volunteered totake an experimental drug: OSU6162. After one dose her choreadecreased from 40 to 2 movements every minute. And she could feedherself and drink without spilling, and she had no falls for theduration of the study. And all this with minimal transient sideeffects.IT sounds almost too good to be true. But wouldn't a drug like thisbe great?Well . . right now, a whole10 years later we finally DO have achance to try this same kind of drug in the improved 2009 version.This drug is ACR16 now in clinical trial in 17 centers over NorthAmerica.And its not just for chorea. In an earlier short trial (in Europe)it appeared to broadly improve symptoms: motor (chorea and dystonia),emotional (improved depression and decreased anxiety) and improvedmeasures of cognition. AND had no more side effects than placebo.My opinion: We should be running = not walking = to sign up for thisone. If it turns out to be as good as the first one looked, we'llfinally get a very good drug for Huntington. Participating sites at: http://clinicaltrials.gov/ct2/show/NCT00724048?term=Huntington%27s+disease&rank=16With hope and best wishes for us all,